Authors

Dejan Juric, MD, Massachusetts General Hospital

Latest:

Future Directions for the Management of HR+ Breast Cancer

Andrew D. Seidman, MD; Aditya Bardia, MD, MPH; Dejan Juric, MD; Nicholas McAndrew, MD, MSCE; and Hope S. Rugo, MD, share closing thoughts on the current and future treatment landscape for the management of HR+ breast cancer.

Andrew Laccetti, MD, MS

Latest:

Dr Laccetti on PSA Responses With Masofaniten Plus Enzalutamide in mCRPC

Andrew Laccetti, MD, MS, discusses phase 1 findings from a phase 1/2 trial investigating masofaniten in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer.

Anil K. Sood, MD

Latest:

Dr. Sood on Navigating Frontline Maintenance Therapy in Ovarian Cancer

Anil K. Sood, MD, discusses navigating frontline maintenance therapy in ovarian cancer.

Ori Barzilai, MD

Latest:

Overall Survival After Surgery for Spinal Metastases Has Improved Over the Past Two Decades

Postoperative survival after surgery for spinal metastases has improved over the past 20 years, particularly in patients with kidney, breast, lung, and colon tumors metastatic to the spine.

Susan Bal, MD, O'Neal Comprehensive Cancer Center at UAB

Latest:

Dr Bal on Updated Findings With BMS-986393 in Relapsed/Refractory Multiple Myeloma

Susan Bal, MD, discusses updated safety and efficacy data from a phase 1 study evaluating the GPRC5D-targeted autologous CAR T-cell therapy BMS-986393 in relapsed/refractory multiple myeloma, including in patients with prior BCMA-directed therapy.

Nicholas Coupe, MBBS, PhD

Latest:

Dr Coupe on the Background of IMM60 With Pembrolizumab in Melanoma or NSCLC

Nicholas Coupe, MBBS, PhD, discusses the rationale for investigating IMM60 with pembrolizumab in patients with advanced melanoma or metastatic non-small cell lung cancer, as well as key background information that led to this investigation.

Will Pizii

Latest:

A Breakthrough for the “Lab Brat”

Building on research his father conducted decades earlier, Robert Orlowski, MD, PhD, redefined myeloma treatment.

Ghayas C. Issa, MD

Latest:

Dr Issa on the Efficacy and Safety of Revumenib in R/R KMT2A+ Leukemias

Ghayas C. Issa, MD, discusses the efficacy of revumenib in relapsed or refractory KMT2A-rearranged leukemias.

Amanda Blackmon, DO

Latest:

Ongoing Research on MRD Detection May Shift Outcomes for Posttransplant AML

The prediction of relapse following treatment with allogeneic stem cell transplant in patients with acute myeloid leukemia in first complete remission remains an unmet need due to limitations attributed to measurable residual disease detection methods.

Bijal Shah, MD, MS

Latest:

Indirect Comparison of Efficacy of Zanubrutinib Versus Acalabrutinib in the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma

The study assessed the comparative efficacy of zanubrutinib vs acalabrutinib in patients with R/R MCL, in the absence of head-to-head clinical trials, using population-adjusted indirect treatment comparison via simulated treatment comparison approach. Data source for the efficacy of zanubrutinib was informed by the pooled individual patient-level data from 2 clinical trials: BGB-3111-206 (NCT03206970) and BGB-3111-AU-003 (NCT02343120). The efficacy of acalabrutinib was informed by the published aggregated data of the ACE-LY-004 trial (NCT02213926).

Martin Hutchings, MD, PhD, Copenhagen University Hospital

Latest:

Rapid Readouts: Phase 1/2 Study of Epcoritamab in R/R B-cell NHL

Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute

Latest:

Rapid Readouts: Phase 1/2 KRYSTAL-1 Trial

Georg Lenz, MD

Latest:

Dr. Lenz on the European Approval of Liso-cel in Relapsed/Refractory LBCL

Georg Lenz, MD, discussed the European approval of lisocabtagene maraleucel in relapsed/refractory large B-cell lymphoma.

Iván Márquez Rodas, MD, PhD

Latest:

Dr. Márquez Rodas on the Preliminary Efficacy of BO-112/Pembrolizumab in Advanced Melanoma

Iván Márquez Rodas, MD, PhD, discusses the preliminary results of the phase 2 SPOTLIGHT203 trial, which is evaluating the efficacy and safety of BO-112 plus pembrolizumab in patients with advanced melanoma.

Ellen Ball, ANP-FNP

Latest:

Biomarker Testing Standards-of-Care in Breast and Lung Cancer

The panel shares their recommendations for biomarker testing standard-of-care in breast cancer and lung cancer.

Tracy I. George, MD

Latest:

Dr George on the Limitations of Current Diagnostic Tools in Detecting KIT D816V Mutations in ISM

Tracy I. George, MD, discusses and how ultra-sensitive duplex sequencing may address key limitations of current diagnostic tools for indolent systemic mastocytosis.

Anurag Agrawal, MD

Latest:

Strategies for Adverse Effect Management and Treatment Optimization With Anti-GD2 Monoclonal Antibodies in R/R

Giselle Sholler, MD, and Anurag Agrawal, MD, explain how proper preparation, a well-trained team, and multidisciplinary support are crucial for managing the adverse effects from anti-GD2 monoclonal antibody agents like naxitamab.

Deborah M. Stephens, DO

Latest:

CAR T-Cell Therapies in CLL

Take-home messages from ASH 2021 regarding the role of CAR T-cell therapies in chronic lymphocytic leukemia.

Pauline Funchain, MD

Latest:

Dr. Funchain on the Rationale for the SWOG S1404 Trial in Melanoma

Pauline Funchain, MD, discusses the rationale for the phase 3 SWOG S1404 trial in high-risk resected melanoma.

Stéphane Champiat MD, PhD

Latest:

Dr. Champiat on Early Efficacy of SOT101 Plus Pembrolizumab in Solid Tumors

Stéphane Champiat MD, PhD, discusses early efficacy seen with the combination of SOT101 and pembrolizumab in solid tumors.